September 30, 2019 11:19 AM EDT

Merck touts Phase III data for antibacterial Recarbrio; Sanofi to ax 200 jobs in Japan — report

Kathy Wong

Editor

→ According to an anonymous source who reported to Reuters, French drugmaker Sanofi plans to ax 200 jobs in Japan across sales, regulatory affairs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck touts Phase III data for antibacterial Recarbrio; Sanofi to ax 200 jobs in Japan — report

Kathy Wong

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Mer­ck touts Phase III da­ta for an­tibac­te­r­i­al Re­car­brio; Sanofi to ax 200 jobs in Japan — re­port

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Merck touts Phase III data for antibacterial Recarbrio; Sanofi to ax 200 jobs in Japan — report